EUVIMEDEUVIMED entdecken
Crossref

Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumours

Pauline Bourdeleau, Johanna Pokossy-Epée, Olivia Hentic, Matthieu Tihy iD, Zaima Afzal Awan, Anne Couvelard, Maxime Ronot, Vinciane Rebours, Philippe Ruszniewski, Jérôme Cros iD, Louis de Mestier iD

Endocrine-Related Cancer · 2025

DOI: 10.1530/erc-24-0321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Pauline Bourdeleau und 10 weiteren Autor:innen. Hauptthemen laut MEDLINE: Ki-67 Antigen, Pancreatic Neoplasms, Neuroendocrine Tumors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic neuroendocrine tumours (PanNETs) have intra-tumour heterogeneity, notably regarding the Ki-67 index, which is a major prognostic factor. The temporal evolution of PanNET biology is poorly known. We aimed to study the prognostic impact of the temporal evolution of Ki-67 and other molecular markers (MEN1, ATRX/DAXX and PDX1/ARX) in PanNETs. We retrospectively studied 109 patients with sporadic PanNETs and serial tumour samples ( n = 286), in which we measured the Ki-67 index and the expression of the other markers. Variables associated with shorter overall survival (OS) and Ki-67 increase over time were explored using multivariable analyses. The median time between the initial and last samples was 49.4 months, with a median variation in Ki-67 of +4% (interquartile range (IQR): −1 to +15%; P < 0.001) and +0.5%/year (IQR: −0.2 to +3.3%). Tumour grade increased in 36% of cases. At multivariable analysis, an increase in Ki-67 ≥ 2%/year was associated with shorter OS (HR 1.96, 95% CI [1.02–3.73], P = 0.041). This variation was more common in patients who received alkylating agents (OR 4.47, 95% CI [1.48–15.38], P = 0.011) and was less common in those who achieved tumour control with somatostatin analogues (OR 0.27, 95% CI [0.08–0.82], P = 0.027). MEN1 and ATRX/DAXX expressions were stable over time, while the proportion of alpha-like signatures (PDX1−/ARX+) decreased ( P = 0.016); none was associated with Ki-67 nor influenced prognosis. Overall, an increase in PanNET grade and Ki-67 index is frequent over time, indicates a poorer prognosis and is promoted by alkylating agents. Rebiopsy during PanNET evolution seems relevant to adjust prognosis evaluation and therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ki-67 AntigenPancreatic NeoplasmsNeuroendocrine TumorsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultPrognosisBiomarkers, TumorX-linked Nuclear ProteinAged, 80 and over

Stichwörter der Autor:innen

Ki-67 indexevolutionintra-tumour heterogeneitymetastasespancreatic neuroendocrine tumours

Substanzen

Ki-67 AntigenBiomarkers, TumorX-linked Nuclear ProteinATRX protein, human

Autor:innen und Institutionen

ORCID-Profile: Matthieu Tihy, Jérôme Cros, Louis de Mestier

Zitieren

APA

Bourdeleau, P., Pokossy-Epée, J., Hentic, O., Tihy, M., Awan, Z. A., Couvelard, A., Ronot, M., Rebours, V., Ruszniewski, P., Cros, J., & de Mestier, L. (2025). Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumours. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0321

Vancouver

Bourdeleau P, Pokossy-Epée J, Hentic O, Tihy M, Awan ZA, Couvelard A, et al. Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumours. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0321

BibTeX
@article{Bourdeleau2025,
  author = {Bourdeleau, Pauline and Pokossy-Epée, Johanna and Hentic, Olivia and Tihy, Matthieu and Awan, Zaima Afzal and Couvelard, Anne and Ronot, Maxime and Rebours, Vinciane and Ruszniewski, Philippe and Cros, Jérôme and de Mestier, Louis},
  title = {Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumours},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  doi = {10.1530/erc-24-0321}
}
Kostenlos starten →